Research programme: reperfusion injury therapies - GENOPIA Biomedical

Drug Profile

Research programme: reperfusion injury therapies - GENOPIA Biomedical

Alternative Names: Reperfusion injury therapies research programme - GENOPIA Biomedical

Latest Information Update: 24 Feb 2010

Price : $50

At a glance

  • Originator GENOPIA Biomedical
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Reperfusion injury; Stroke

Most Recent Events

  • 24 Feb 2010 Discontinued - Preclinical for Stroke in Germany (unspecified route)
  • 24 Feb 2010 Discontinued - Preclinical for Reperfusion injury in Germany (unspecified route)
  • 04 Aug 2004 Preclinical trials in Stroke in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top